Related Experiment Video

Updated: Jan 22, 2026

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
10:35

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

18.8K

Identifying and targeting angiogenesis-related microRNAs in ovarian cancer

Xiuhui Chen1,2, Lingegowda S Mangala3,4, Linda Mooberry5

  • 1Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Oncogene
|July 11, 2019
PubMed

Insights

MicroRNAs regulate ovarian tumor angiogenesis. Researchers developed a novel nanoparticle delivery system for miR-204-5p inhibitors, effectively suppressing tumor growth and offering new therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Nanotechnology

Background:

  • Current anti-angiogenic cancer therapies targeting vascular endothelial growth factor show limited efficacy.
  • MicroRNA (miRNA) deregulation is implicated in tumor angiogenesis, presenting a potential therapeutic target.
  • Effective delivery systems are crucial for miRNA-based cancer therapies.

Purpose of the Study:

  • To investigate the role of miR-204-5p in ovarian tumor angiogenesis.
  • To develop and evaluate a novel nanoparticle system for delivering miRNA inhibitors to tumors.
  • To assess the therapeutic potential of targeting miR-204-5p in ovarian cancer.

Main Methods:

  • miRNA profiling of patient data.
  • In vitro and in vivo experiments to study miR-204-5p function.
  • Development of reconstituted high-density lipoprotein-nanoparticles (rHDL-NPs) for targeted delivery.
  • Administration of miR-204-5p inhibitor (miR-204-5p-inh) via rHDL-NPs in a tumor model.

Main Results:

  • miR-204-5p was identified as a promoter of angiogenesis in ovarian tumors, acting via THBS1.
  • rHDL-NPs effectively delivered miR-204-5p-inh to tumor sites by targeting scavenger receptor class B type 1 (SCARB1).
  • Treatment with miR-204-5p-inh encapsulated in rHDL-NPs suppressed ovarian tumor growth.

Conclusions:

  • miR-204-5p plays a significant role in promoting ovarian tumor angiogenesis.
  • rHDL-NPs represent a promising delivery platform for miRNA-based cancer therapeutics.
  • Targeting miR-204-5p offers a novel therapeutic strategy for ovarian cancer.

More Related Videos

Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis11:51

Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis

Published on: November 18, 2019

6.3K
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

3.0K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.7K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.7K
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
3.6K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.4K